Abstract |
Tadalafil, which was commercialized in 2009, is a potent and selective phosphodiesterase type 5 ( PDE5) inhibitor, and may be a safe and effective therapeutic alternative for patients with class II and III pulmonary hypertension (PH) in the World Health Organization's classification--as stated in the Clinical Practice Guidelines for the Diagnosis and Treatment of PH of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)--providing benefits in exercise tolerance, delaying clinical deterioration and improving quality of life. Given the greater half-life of this drug, allowing a single oral dose of 40 mg per day, tadalafil could improve therapeutic compliance--thus facilitating treatment adherence--among patients with PH.
|
Authors | Javier Gaudó Navarro, Antonio Sueiro Bendito |
Journal | Archivos de bronconeumologia
(Arch Bronconeumol)
Vol. 47 Suppl 7
Pg. 26-31
( 2011)
ISSN: 1579-2129 [Electronic] Spain |
Vernacular Title | Tadalafilo: nuevos aspectos de la inhibición de la fosfodiesterasa tipo 5 en el tratamiento de la hipertensión pulmonar. |
PMID | 23351473
(Publication Type: English Abstract, Journal Article, Review)
|
Copyright | Copyright © 2011 Sociedad Española de Neumología y Cirugía Torácica. Published by Elsevier Espana. All rights reserved. |
Chemical References |
- Carbolines
- Phosphodiesterase 5 Inhibitors
- Tadalafil
- Cyclic Nucleotide Phosphodiesterases, Type 5
- Cyclic GMP
|
Topics |
- Carbolines
(adverse effects, pharmacology, therapeutic use)
- Cyclic GMP
(metabolism)
- Cyclic Nucleotide Phosphodiesterases, Type 5
(physiology)
- Double-Blind Method
- Drug Interactions
- Exercise Tolerance
(drug effects)
- Humans
- Hypertension, Pulmonary
(drug therapy, enzymology)
- Molecular Structure
- Phosphodiesterase 5 Inhibitors
(adverse effects, pharmacology, therapeutic use)
- Prognosis
- Quality of Life
- Randomized Controlled Trials as Topic
- Second Messenger Systems
- Tadalafil
|